Natural Killer Cells

[Century Therapeutics] Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.

[Nature Communications] Investigators showed the administration of allogeneic human peripheral blood natural killer cells delays viral rebound following interruption of anti-retroviral therapy in humanized mice infected with HIV-1.

[Oncoimmunology] The authors investigated the efficacy of CD29- and CD44-targeted NIR-PIT (CD29-PIT and CD44-PIT, respectively) in the B16 melanoma model, which was highly pigmented.

[Molecular Biology Reports] IL-21 has profound effects on tumor growth and immunosurveillance of colitis-associated tumourigenesis, thereby emphasising its involvement in the pathogenesis of colorectal cancer.

[Cancer Immunology Research] Investigators combined intratumoral STimulator of INterferon Genes (STING) agonist therapy with systemically injected extended half-life IL2 and anti–PD-1 checkpoint blockade to drive innate and adaptive antitumor immunity in models of triple-negative breast cancer.

[Cellular & Molecular Immunology] Scientists summarize the recent advances in expansion strategies with or without genetic manipulation of NK cells derived from various cellular sources.